Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Targeted Therapy;  Immunotherapy

Tumour Site

Presenters

Anna Minchom

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

A.R. Minchom1, K. Culm2, E. Garmey3, L. Makris4, M.L. Johnson5, D. Sommerhalder6, E. Garralda7, J. Henry8, M. Yang9, L. Mei10, M.M. Cotreau11, A. Goenaga12, D. Burzyn13, Z. Yang14, R. Wei15, V. Chhaljani16, J. Mascola17, G. Nabel18, E.E. Dumbrava19

Author affiliations

  • 1 Drug Development Unit, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 2 Clinical Development, ModeX Therapeutics, an OPKO Health Company, 02493 - Weston/US
  • 3 Medical Oncology, CMO Consulting, 01742 - Concord/US
  • 4 Consultant, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 5 Lung Cancer Research, Sarah Cannon Research Institute-Cancer Centre, 37203 - Nashville/US
  • 6 Oncology, NEXT OncologyTM, 78229 - San Antonio/US
  • 7 Early Drug Development Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 8 Research, SCRI - Sarah Cannon Research Institute, 37203 - Nashville/US
  • 9 Program Management, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 10 Consultant, Qualvantage Consulting, 02474 - Arlington/US
  • 11 Consultant, MMC Biopartners, 02451 - Carlisle/US
  • 12 Clinical Development, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 13 Translational Medicine, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 14 Discovery Research, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 15 Biologics Discovery, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 16 Chief Technology Officer, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 17 Chief Scientific Officer, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 18 Chief Executive Officer, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US
  • 19 Investigational Cancer Therapeutics Department, The University of Texas MD Anderson Cancer Center - Main Building, 77030 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 680TiP

Background

MDX2001 is a tetraspecific T cell engager antibody recognizing CD3 and CD28 on human T cells, and c-MET and TROP2 on certain tumors. Anti-CD3 provides the primary signal for T cell activation while anti-CD28 delivers the secondary signal for enhanced T cell activation, survival and proliferation. Combinatorial targeting of c-MET and TROP2 by MDX2001, either on the same or different cancer cells, is hypothesized to provide more effective engagement of tumor cells by T cells and may better address tumor heterogenicity and treatment escape/resistance.

Trial design

This Phase 1/2a multicenter, open-label clinical trial explores MDX2001 in patients with selected advanced solid tumor malignancies. The study design consists of Phase 1a dose escalation guided by a Bayesian Optimal Interval design with a target maximum tolerated dose toxicity rate of 30%, a Phase 1b dose expansion in a single indication, and Phase 2a recommended Phase 2 dose (RP2D) expansion in a single indication. Patients with selected tumors known to have high rates of TROP2 or c-MET expression are eligible for Phase 1a where escalating doses of MDX2001 are given intravenously in sequential escalation cohorts. In a single Phase 1b indication, patients will be randomized 1:1 into 2 dose cohorts using a Bayesian Optimal Phase 2 (BOP2) design. Once a RP2D is determined, Phase 2a will enroll approximately 30 patients into a single cohort using a BOP2 design. The primary objectives of this study are to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors. Secondary objectives include characterizing MDX2001 pharmacokinetics, immunogenicity, and evaluating the relationship between baseline tumor target protein expression and clinical benefit. Patients will have radiographic tumor assessments every 8 weeks and will continue to receive treatment until disease progression per RECIST v1.1 (as assessed by the investigator), unacceptable toxicity, withdrawal of consent or the sponsor terminates the study, whichever occurs first. The study will be conducted in United States,United Kingdom, Europe, and Asia.

Clinical trial identification

NCT06239194.

Editorial acknowledgement

Legal entity responsible for the study

ModeX Therapeutics, an OPKO Health Company.

Funding

ModeX Therapeutics, an OPKO Health Company.

Disclosure

A.R. Minchom: Financial Interests, Personal, Other, Expenses: Amgen Pharmaceuticals, Loxo oncology; Financial Interests, Personal, Invited Speaker: Bayer Pharmaceuticals, Chugai Pharmaceuticls, GSK, Janssen Pharmaceuticals, Merck Pharmaceuticals; Financial Interests, Personal, Advisory Board: Faron Pharmaceuticals, GSK, Janssen Pharmaceuticals, Merck Pharmaceuticals, Takeda, Genmab; Financial Interests, Institutional, Other, Research funding: MSD, Merck Pharmaceuticals; Financial Interests, Personal, Other, Honoraria: Novartis Oncology. K. Culm: Financial Interests, Personal, Stocks or ownership: BMS; Financial Interests, Personal, Full or part-time Employment: ModeX Therapeutics. E. Garmey: Financial Interests, Personal, Other, Paid medical consultant: Grifols, Aldeyra, Bicycle Therapeutics, Circle Pharma, Finch Therapeutics, Genocea Biosciences, Genzada, Gigagen, H3 BioScience, HiFi Bio, ImmuneSensor Therapeutics, ImmunoMet, Linnaeus Therapeutics, ModeX Therapeutics, NED BioSystems, Novita Pharma, OncoHeroes, Raze Therapeutics, Sensei Therapeutics, Shasqi, Tagworks, Targimmune, Tarveda, X4 Therapeutics; Non-Financial Interests, Member of Board of Directors: Beth Israel Deaconess Hospital. L. Makris: Financial Interests, Personal, Speaker, Consultant, Advisor: ModeX Therapeutics, Various. M.L. Johnson: Financial Interests, Institutional, Other, Consulting: AbbVie, Amgen, Arcus Biosciences, Arrivent, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Immunocore, Janssen, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, Molecular Axiom, Novartis, Pyramid Biosciences, Alentis Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio Limitied, Fate Therapeutics, Gilead Sciences, Hookipa Biotech, Lilly, Normunity, Novocure, Pfizer, Revolution Medicines, Sanofi-Aventis, SeaGen, Synthekine, Takeda Pharmaceuticals, VBL Therapeutics; Financial Interests, Institutional, Research Grant: AbbVie, Adaptimmune, Amgen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, City of Hope National Medical Center, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchinson MediPharma, Ideaya Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Kartos Therapeutics, Loxo Oncology, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight BioPharmaceuticals/Birdie BioPharmaceuticals, Shattuck Labs, Silicon Therapeutics, Syndax Pharmaceuticals, Takeda Pharmaceuticals, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, Tmunity Therapeutics, Turning Point Therapeutics, Vyriad, Y-mAbs Therapeutics, ArriVent BioPharma, Bayer, LockBody Therapeutics, Taiho Oncology, Conjupro, Immuneering Corporation, Impact Therapeutics, NextPoint Therapeutics, OncoC4, Summit Therapeutics, Systimmune, TheRas, Vividion. D. Sommerhalder: Financial Interests, Personal, Other, Ad-hoc advisory role: Syneos SAG; Financial Interests, Personal, Other, Medical consulting: Guidepoint; Financial Interests, Institutional, Full or part-time Employment, Employed as a physician by Texas Oncology, a for-profit entity.: Texas Oncology/US Oncology; Financial Interests, Personal, Stocks/Shares, Shareholder: NEXT Oncology, Texas Oncology; Financial Interests, Institutional, Local PI: AbbVie, Astellas, BJ Biosciences, BioNTech, Biomea Fusion, Boehringer Ingelheim, Bristol Myers Squibb, Fate Therapeutics, Gilead Sciences, Iconovir Bio, Immuneering, Kura Oncology, MediLink Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, NGM BioPharmaceuticals, Navire, Nimbus Saturn, OncoResponse Inc, Parthenon, Pfizer, Revolution Medicines, Symphogen, Tachyon Therapeutics, Teon Therapeutics, Tyligand Bioscience, Vividion Therapeutics, ZielBio. E. Garralda: Financial Interests, Personal, Invited Speaker: MSD, Roche, Thermo Fisher, Novartis, SeaGen; Financial Interests, Personal, Advisory Board: Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, Hengrui, F-Star Therapeutics, Sanofi, Incyte, Medscape; Financial Interests, Personal, Full or part-time Employment: NEXT Oncology; Financial Interests, Personal, Stocks/Shares: 1TRIALSP; Financial Interests, Institutional, Funding: Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho; Financial Interests, Institutional, Research Grant: BeiGene, Janssen. J. Henry: Financial Interests, Personal, Principal Investigator: Various. M. Yang, D. Burzyn, V. Chhaljani: Financial Interests, Personal, Full or part-time Employment: ModeX Therapeutics. M.M. Cotreau: Financial Interests, Personal, Advisory Role: ModeX Therapeutics; Financial Interests, Personal, Stocks/Shares: Abcuro, Alnylam, ImmunoGen. A. Goenaga: Financial Interests, Personal, Full or part-time Employment: ModeX Therapeutics; Financial Interests, Personal, Stocks/Shares: Pfizer. Z. Yang: Financial Interests, Personal, Full or part-time Employment: ModeX Therapeutics; Financial Interests, Personal, Stocks/Shares: OPKO Health. R. Wei: Financial Interests, Personal, Full or part-time Employment: ModeX Therapeutics; Financial Interests, Personal, Stocks/Shares: Sanofi, OPKO Health. J. Mascola: Financial Interests, Personal, Leadership Role: ModeX Therapeutics. G. Nabel: Financial Interests, Personal, Leadership Role: ModeX Therapeutics, Siga Technologiest, Candel Therapeutics; Financial Interests, Personal, Advisory Role: OKPO Health; Financial Interests, Personal, Stocks/Shares: Moderna, Medtronic, Lyell Immunopharma, Accolade Hospice. E.E. Dumbrava: Financial Interests, Institutional, Other, Research/grant funding: Bayer HealthCare Pharmaceuticals, Immunocore Ltd, Amgen, Aileron Therapeutics, Compugen Ltd, Gilead, BOLT Therapeutics, Aprea Therapeutics, Bellicum, PMV Pharma, Triumvira, Seagen Inc, Mereo BioPharma 5 Inc, Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Mersana Therapeutics, Poseida, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: PMV Pharma; Financial Interests, Personal, Advisory Board: BOLT Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.